Novartis AG

Things are starting to heat up in the already hot pharmaceutical sector – especially as it relates to mergers and acquisitions. Only days after Onyx Pharmaceuticals (NASDAQ: ONXX) said it rejected an $8.7 billion buyout offer from Amgen (NASDAQ: AMGN), according to Reuters, the company has...

It’s a simple matter of math. The more diseases there are to treat, the more profit there is to be made – by drug companies that produce the medicines designed to treat those diseases. The Wall Street Journal reported Wednesday that the 5th edition of the Diagnostic and Statistic Manual of...

It’s a sign of the times in health care. If you can’t generate growth, buy it. The New York Times sounded that familiar theme in reporting the pending acquisition Monday of Rochester, N ew York-based Bausch & Lomb by Canadian drugmaker Valeant Pharmaceuticals (NYSE: VRX). J. Michael...

Novartis AG (NYSE: NVS) reported after the close today, November 3rd The New England Journal of Medicine published a study which found patients taking Afinitor tablets saw a decrease in the size of their subependymal giant cell astrocytoma. Astrocytoma's are a benign brain tumor associated with TB...

Biotech company Human Genome Sciences, Inc. (Nasdaq: HGSI) reported that a study has showed that a monthly dose of its drug Zalbin to treat hepatitus C is just as effective as the current weekly treatment. Human Genome Sciences is working with Novartis AG (NYSE: NVS) on the drug, with Novartis AG...